pimavanserin for Parkinson's psychosis
Selected indexed studies
- Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. (Lancet, 2014) [PMID:24183563]
- Parkinson's disease psychosis: presentation, diagnosis and management. (Neurodegener Dis Manag, 2017) [PMID:29160144]
- Pimavanserin for psychosis in Parkinson's disease dementia: Subgroup analysis of the HARMONY Trial. (Parkinsonism Relat Disord, 2024) [PMID:38113700]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Parkinson's disease psychosis: presentation, diagnosis and management. (2017) pubmed
- Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. (2014) pubmed
- Pimavanserin in Parkinson's Disease-induced Psychosis: A Literature Review. (2019) pubmed
- Pimavanserin for psychosis in Parkinson's disease dementia: Subgroup analysis of the HARMONY Trial. (2024) pubmed
- Changing the treatment paradigm for Parkinson's disease psychosis with pimavanserin. (2019) pubmed
- Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis. (2018) pubmed
- Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis. (2017) pubmed
- Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis. (2017) pubmed
- Pimavanserin: A Truly Effective Treatment for Parkinson's Disease Psychosis? A Review of Interventions. (2023) pubmed
- Second-generation antipsychotics for Parkinson's disease psychosis: A systematic review and network meta-analysis. (2024) pubmed